GST-pi and P-170 co-expression in multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Multiple myeloma is a plasma cell malignancy.
• Drug resistance is a major challenge in multiple myeloma treatment.
• Mechanisms of drug resistance, including P-glycoprotein (P-170) and glutathione-S-transferase pi (GST-pi) expression, are not fully understood in this context.

Purpose of the Study:

• To investigate the expression of P-glycoprotein (P-170), glutathione-S-transferase pi (GST-pi), and p-21 in plasma cells of multiple myeloma patients.
• To determine the correlation of these markers with clinical and prognostic parameters.
• To assess changes in marker expression before and after therapy.

Main Methods:

• Immunocytochemical detection was used to analyze bone marrow plasma cells from 40 multiple myeloma patients.
• Expression levels of P-170, GST-pi, and p-21 were quantified.
• Patients were categorized as treated or untreated, and samples were analyzed pre- and post-therapy.

Main Results:

• P-170 and GST-pi were expressed in a high percentage of samples (72% and 82%, respectively), irrespective of clinical or prognostic factors.
• A significant positive correlation and co-expression (91%) were observed between GST-pi and P-170.
• Expression of both markers increased after therapy, while p-21 expression showed no association with these resistance mechanisms.

Conclusions:

• Multiple myeloma exhibits diverse drug resistance mechanisms involving P-170 and GST-pi.
• These resistance markers are present in both treated and untreated patients and can be upregulated by therapy.
• Further research is needed to elucidate the role of p-21 and other factors in myeloma drug resistance.